What do most Americans think of cost-effectiveness research in health care?


Autoria(s): Graves, Nicholas
Data(s)

20/03/2015

Resumo

My impression is that explicit data on the cost-effectiveness of different health care services are not valued highly by US policy makers. An example is a recent decision to approve ipilimumab for the treatment of metastatic melanoma. The extra health benefit over standard treatment is 2.1 months in previously untreated patients and the cost is $120,000 for 4 doses. This is poor value for money. Had $120,000 been allocated to an intensive lifestyle modification programme for diabetes risk (Diabet Med. 2004 Nov;21(11):1229-36) then 67 years of life or 800 months could have been returned. A massive increase in health benefits for the same costs.

Formato

application/pdf

Identificador

http://eprints.qut.edu.au/84036/

Publicador

Wordpress AusHSI Blog

Relação

http://eprints.qut.edu.au/84036/1/84032.pdf

http://aushsiblog.com/?p=102

Graves, Nicholas (2015) What do most Americans think of cost-effectiveness research in health care? AusHSI Blog, 20 March.

Fonte

Faculty of Health; Institute of Health and Biomedical Innovation; School of Public Health & Social Work

Palavras-Chave #Health Services Research
Tipo

Other